Takabayashi Kensuke, Yamashita Yugo, Morimoto Takeshi, Chatani Ryuki, Kaneda Kazuhisa, Nishimoto Yuji, Ikeda Nobutaka, Kobayashi Yohei, Ikeda Satoshi, Kim Kitae, Inoko Moriaki, Takase Toru, Tsuji Shuhei, Oi Maki, Takada Takuma, Otsui Kazunori, Sakamoto Jiro, Ogihara Yoshito, Inoue Takeshi, Usami Shunsuke, Chen Po-Min, Togi Kiyonori, Koitabashi Norimichi, Hiramori Seiichi, Doi Kosuke, Mabuchi Hiroshi, Tsuyuki Yoshiaki, Murata Koichiro, Nakai Hisato, Sueta Daisuke, Shioyama Wataru, Dohke Tomohiro, Nishikawa Ryusuke, Ono Koh, Kimura Takeshi
Department of Cardiology, Hirakata Kohsai Hospital, 1-2-1, Fujisakashigashimachi, Hirakata-shi, Osaka, 573-0153, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
J Intensive Care. 2024 Nov 5;12(1):45. doi: 10.1186/s40560-024-00755-x.
Extracorporeal membrane oxygenation (ECMO) might be required as a treatment option in patients with critical pulmonary embolism (PE). However, the clinical features and outcomes of the use of ECMO for critical acute PE are still limited. The present study aimed to clarify the clinical characteristics, management strategies and outcomes of patients with acute PE requiring ECMO in the current era using data from a large-scale observational database.
We analyzed the data of the COMMAND VTE Registry-2: a physician-initiated, multicenter, retrospective cohort study enrolling consecutive patients with acute symptomatic venous thromboembolism (VTE). Among 2035 patients with acute symptomatic PE, there were 76 patients (3.7%) requiring ECMO.
Overall, the mean age was 58.4 years, and 34 patients (44.7%) were men. Cardiac arrest or circulatory collapse at diagnosis was reported in 67 patients (88.2%). The 30-day incidence of all-cause death was 30.3%, which were all PE-related deaths. The 30-day incidence of major bleeding was 54.0%, and the vast majority of bleedings were procedure site-related bleeding events and surgery-related bleeding (22.4%). The 30-day incidence of all-cause death was 6.3% in 16 patients with surgical intervention, 43.8% in 16 patients with catheter intervention, 25.0% in 16 patients with thrombolytic therapy, and 39.3% in 28 patients with anticoagulation only.
The current large real-world VTE registry in Japan revealed clinical features and outcomes of critical acute PE requiring ECMO in the current era, which suggested several unmet needs for future clinical trials.
对于重症肺栓塞(PE)患者,体外膜肺氧合(ECMO)可能是一种治疗选择。然而,ECMO用于重症急性PE的临床特征和结局仍很有限。本研究旨在利用大规模观察性数据库的数据,阐明当代需要ECMO的急性PE患者的临床特征、管理策略和结局。
我们分析了COMMAND VTE注册研究-2的数据:这是一项由医生发起的、多中心、回顾性队列研究,纳入了连续的急性症状性静脉血栓栓塞症(VTE)患者。在2035例急性症状性PE患者中,有76例(3.7%)需要ECMO。
总体而言,平均年龄为58.4岁,34例(44.7%)为男性。67例(88.2%)患者在诊断时出现心脏骤停或循环衰竭。全因死亡的30天发生率为30.3%,均为PE相关死亡。大出血的30天发生率为54.0%,绝大多数出血是手术部位相关出血事件和手术相关出血(22.4%)。16例接受手术干预的患者全因死亡的30天发生率为6.3%,16例接受导管介入的患者为43.8%,16例接受溶栓治疗的患者为25.0%,28例仅接受抗凝治疗的患者为39.3%。
日本当前大型真实世界VTE注册研究揭示了当代需要ECMO的重症急性PE的临床特征和结局,这提示了未来临床试验中一些未满足的需求。